• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Clinical Trials

Glucotrack can proceed with long-term glucose monitor study in Australia

May 13, 2025 By Sean Whooley

GlucoTrack updated Logo (1)

Glucotrack (Nasdaq:GCTK) announced today that it received a hospital’s ethical approval to study its continuous blood glucose monitor (CBGM). The St. Vincent’s Hospital Melbourne Human Research Ethics Committee (HREC) gave the nod for a long-term clinical study. It plans to include participants with both type 1 and type 2 diabetes using the CBGM. Rutherford, New […]

Filed Under: Business/Financial News, Clinical Trials, Diabetes, Drug-Device Combinations, Implants, Patient Monitoring, Technology Tagged With: Glucotrack

Cordis shares positive study results from multiple drug-eluting balloon studies

April 25, 2025 By Sean Whooley

Cordis Selution SLR drug-eluting balloon

Cordis announced new data from two major peripheral studies evaluating its Selution SLR drug-eluting balloon. The Miami Lakes, Florida-based company presented 12-month results from the SUCCESS PTA study at the Charing Cross Symposium in London. It then shared SELUTION SFA Japan three-year results today at the Japan Endovascular Treatment Conference in Osaka. According to Cordis, the studies […]

Filed Under: Cardiovascular, Clinical Trials, Drug-Device Combinations, Featured, Vascular Tagged With: cordis

Data backs Boston Scientific drug-eluting stent

April 23, 2025 By Sean Whooley

Boston Scientific Eluvia drug-eluting vascular stent system (1)

Boston Scientific today shared study data supporting the use of its Eluvia drug-eluting stent for treating PAD. The company shared multiple new clinical data sets at Charing Cross 2025 in London today. Findings reinforced the growing body of evidence supporting the Eluvia stent for treating peripheral artery disease (PAD) — particularly in the superficial femoral […]

Filed Under: Cardiovascular, Clinical Trials, Drug-Device Combinations, Featured, Implants, Stents, Vascular Tagged With: Boston Scientific

R3 Vascular reports first patient treated in next-gen drug-eluting scaffold study

April 22, 2025 By Sean Whooley

R3 Vascular Logo (1)

R3 Vascular announced today that a doctor treated the first patient in the ELITE-BTK pivotal trial of its drug-eluting bioresorbable scaffold. Dr. Brian DeRubertis of New York-Presbyterian and Weill Cornell Medicine treated the first patient. The trial evaluates the company’s next-generation Magnitude drug-eluting bioresorbable scaffold for below-the-knee peripheral arterial disease (PAD). Mountain View, California-based R3 […]

Filed Under: Clinical Trials, Drug-Device Combinations, Implants, Stents, Vascular Tagged With: R3 Vascular

Study says smart infusion pump interoperability can enhance medication delivery

April 15, 2025 By Sean Whooley

Dove Press Infusion Pump interoperability study (1)

A review of several studies highlighted the role smart infusion pump interoperability can play in medication administration. According to the study’s abstract, medication administration issues remain a persistent issue in the U.S. Investigators believe that smart infusion pump interoperability with electronic health records (EHRs) could potentially reduce IV errors. Smart infusion pumps safely deliver IV medications […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Technology

Aptar reports positive adherence results with iPump dose software

April 14, 2025 By Sean Whooley

Aptar Digital health iPump (1) (1)

Aptar Digital Health today announced survey findings showcasing the impact of its iPump connected assistant for medication adherence. The SPEED survey looked at iPump’s effect on adherence to Stallergenes Greer’s sublingual liquid immunotherapy (SLIT). Stallergenes Greer will present findings at the CFA congress (Congrès Francophone d’Allergologie) in Paris this week. iPump, developed in conjunction with […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Patient Monitoring, Pharmaceuticals, Technology Tagged With: aptarpharma

The biggest diabetes tech news out of ATTD 2025

March 24, 2025 By Sean Whooley

Tandem Diabetes Care child wearing mobi pump control IQ+

Last week, Amsterdam played host to this year’s edition of the International Conference on Advanced Technologies & Treatments for Diabetes (ATTD). For the 18th edition of this event, some of the biggest names in diabetes technology put their latest innovations on display. Updates for insulin delivery and glucose monitoring technologies dominated the headlines as many […]

Filed Under: Business/Financial News, Clinical Trials, Diabetes, Drug-Device Combinations, Featured, Patient Monitoring, Technology Tagged With: abbott, ATTD 2025, CamDiab, Dexcom, Insulet, Medtronic, modularmedical, Sequel Med Tech, Tandem Diabetes Care, Ypsomed

Medtronic reports first real-world data on smart insulin pen system

March 20, 2025 By Sean Whooley

Medtronic Simplera CGM InPen Smart MDI system (1)

Medtronic (NYSE:MDT) today announced real-world data supporting the use of its smart insulin pen and CGM sensor combination. The data evaluated Medtronic’s Smart MDI system, which combines the InPen with the Simplera continuous glucose monitor (CGM). Data showed how the system, designed for people with diabetes using multiple daily injections (MDI) when used as intended, […]

Filed Under: Clinical Trials, Diabetes, Drug-Device Combinations, Featured, Patient Monitoring, Technology Tagged With: ATTD 2025, Medtronic

Insulet study shows improvements with Omnipod 5 transitioning from multiple daily injections

March 19, 2025 By Sean Whooley

Insulet Omnipod 5 Abbott FreeStyle Libre 2 Plus

Insulet (Nasdaq:PODD) today announced new Omnipod 5 clinical data highlighting the transition from multiple daily injections (MDI). Investigators shared data from the RADIANT study at the 18th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) in Amsterdam. The randomized controlled trial evaluated the direct transition from MDI to automated insulin delivery (AID). Insulet […]

Filed Under: Business/Financial News, Clinical Trials, Diabetes, Drug-Device Combinations, Featured, Technology Tagged With: ATTD 2025, Insulet

Tandem has positive data for automated insulin delivery in type 2 diabetes population

March 19, 2025 By Sean Whooley

Tandem Diabetes Care Mobi Lifestyle

Tandem Diabetes Care (Nasdaq:TNDM) today announced positive data supporting its automated insulin delivery technology for type 2 diabetes. San Diego-based Tandem won FDA clearance for its Control-IQ+ next-generation algorithm for type 2 diabetes at the end of last month. Just yesterday, the company announced the launch of the algorithm. Control-IQ+ represents the next generation of the […]

Filed Under: Clinical Trials, Diabetes, Drug-Device Combinations, Featured, Technology Tagged With: ATTD 2025, Tandem Diabetes Care

  • « Go to Previous Page
  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • Interim pages omitted …
  • Page 103
  • Go to Next Page »

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS